Its lead candidate is an inhaled peptide designed to dissolve airway-occluding mucus plugs and restore airway patency with high efficacy, potency, and safety. By addressing a shared underlying mechanism across multiple lung diseases, MucoLife Therapeutics aims to transform the treatment paradigm for mucus-mediated respiratory conditions.
MucoLife Therapeutics
MucoLife Therapeutics is a biotech company developing first-in-class therapies targeting pathological mucus obstruction in chronic respiratory diseases such as COPD, cystic fibrosis, and bronchiectasis.
